News and Trends 25 Jan 2018
Novartis Will Bring US Gene Therapy for Blindness to Europe
The Swiss pharma has bought into the gene editing therapy game in a deal with Spark worth $170M (€137M) for commercialization rights outside the US. Novartis first marked out its position as a gene therapy leader in 2012 when it threw its hat into the CAR-T ring. Just a few months after the FDA approved […]